Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Consolidated Diluted EPS Stands At $-5.2884

0

For the period ended 2015-12-31, Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) delivered annual basic consolidated EPS of $-5.2884. In terms of quarterly performance, the basic consolidated EPS was $-5.2884 for the quarter ended 2015-12-31.

What about EPS from continuing operations?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) produced $-5.4022 in basic EPS from continuing operations for the annual period ended 2015-12-31. For the quarter, basic EPS from continuing operations was $-5.4022 for the three-month period ended 2015-12-31.

how much did parent contribute in EPS?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) received basic EPS boost of $-5.2884 from its parent company for the annual period ended 2015-12-31. For quarterly metrics, basic EPS contribution from the parent company was $-5.2884 for the three-month period ended 2015-12-31.

Basic net EPS

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted basic net EPS of $-5.4022 for the annual period ended 2015-12-31. On quarterly basis, the basic net EPS for the quarter ended 2015-12-31 was $-5.4022.

Consolidated diluted EPS

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) produced annual consolidated diluted EPS of $-5.2884 for the period ended 2015-12-31. But consolidated diluted EPS stood at $-5.2884 for the quarter ended 2015-12-31.

Basic diluted EPS

Basic diluted EPS of $-5.4022 came from continuing operation for the annual period ended 2015-12-31. In terms of quarterly performance, diluted EPS from continuing operations was $-5.4022 for the quarter ended 2015-12-31.

Net diluted EPS

The company posted net diluted EPS of $-5.4022 for the annual period ended 2015-12-31. Coming to the quarter, it posted net diluted EPS of $-5.4022 for the three-month period ended 2015-12-31.

Diluted EPS from parent

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) received diluted EPS boost of $-5.2884 from the parent company for the annual period ended 2015-12-31. For the quarter, diluted EPS from the parent was $-5.2884 for the quarter ended 2015-12-31.

For the annual period ended 2015-12-31, Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) produced net basic EPS of $-64.8519. On quarterly basis, it posted basic net EPS of $-64.8519, which was for the three-month period ended 2015-12-31.

The annual average of the company’s basic shares outstanding was 0.2259 for the period ended 2015-12-31. The quarterly average of basic shares outstanding was 0.2259 for the quarter ended 2015-12-31.

The company had diluted shares outstanding of 0.2259 for the annual period ended 2015-12-31 and 0.2259 for the quarterly period ended 2015-12-31.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 11 times, 1 visits today)